biostudies-literatureCella DBristol-Myers SquibbOno PharmaceuticalTakeda Pharmaceutical Co LtdNCI NIH HHSExelixisMemorial Sloan Kettering Cancer CenterIpsen292-303https://www.ebi.ac.uk/biostudies/studies/S-EPMC9479564biostudies-literatureUnknown23(2)<h4>Background</h4>In the CheckMate 9ER trial, patients with advanced renal cell carcinoma who received first-line nivolumab plus cabozantinib had significantly better progression-free survival compared with those given sunitinib. In this study, we aimed to describe the patient-reported outcome (PRO) results from CheckMate 9ER.<h4>Methods</h4>In this open-label, randomised, phase 3 trial done in 125 cancer centres, urology centres, and hospitals across 18 countries, patients aged 18 years or older with previously untreated advanced renal cell carcinoma with a clear-cell component, a Karnofsky performance status of 70% or more, and available tumour tissue were randomly assigned (1:1) via interactive response technology to nivolumab 240 mg intravenously every 2 weeks plus oral cabozantinib 4The Lancet. OncologyPatient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.PMC9479564P30 CA008748Simsek BEjzykowicz FZhang JIvanescu CWallace JFApolo ABCella DSuarez CBlum SIMotzer RJChoueiri TKHamilton MfalsePatient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.<h4>Background</h4>In the CheckMate 9ER trial, patients with advanced renal cell carcinoma who received first-line nivolumab plus cabozantinib had significantly better progression-free survival compared with those given sunitinib. In this study, we aimed to describe the patient-reported outcome (PRO) results from CheckMate 9ER.<h4>Methods</h4>In this open-label, randomised, phase 3 trial done in 125 cancer centres, urology centres, and hospitals across 18 countries, patients aged 18 years or older with previously untreated advanced renal cell carcinoma with a clear-cell component, a Karnofsky performance status of 70% or more, and available tumour tissue were randomly assigned (1:1) via interactive response technology to nivolumab 240 mg intravenously every 2 weeks plus oral cabozantinib 42022-01-01T00:00:00Z2022 Feb2026-05-10T06:51:46.138Z2025-04-05T16:11:33.853ZS-EPMC94795643503243710.1016/S1470-2045(21)00693-810.1016/s1470-2045(21)00693-8